Provided herein are compounds (i.e., fluorogenic amino acids (FgAAs), e.g., compounds of Formulae (I), (II), (III), and (IV)) that can be used in fluorescent labeling of biomolecules (e.g., proteins) and/or cells. Also described herein are methods of labeling and detecting biomolecules and/or cells by incorporating the FgAA compounds described herein into the biomolecules and/or cells (e.g., by enzymatic incorporation). Also provided herein are biomolecules, cells, compositions, and kits comprising the FgAA compounds described herein.

A dye composition dissolvable within a liquid crystal host device (including: polymer dispersed liquid crystal, polymer network liquid crystal, polymer stabilized liquid crystal, liquid crystal displays and similar devices), comprising eutectic mixtures of dichroic metallomesogen molecules. The aforesaid metallomesogen molecules comprise chromophore groups synthesized by physical and chemical mixing methods.

The present invention relates to a process for dyeing keratin fibres, in particular human keratin fibres such as the hair, in one or more steps, comprising the application to said keratin fibres of a composition comprising one or more compounds of formula (I) and/or (II), and also to the use thereof for dyeing keratin fibres, and to a device: in which formula (I) or (II) R.sub.1, R.sub.3, R.sub.4, R.sub.5, R.sub.6, and n are as defined in the description. The compounds of formula (I) according to the invention can give powerful, chromatic and sparingly selective colourings with good colour build-up, which are resistant to the various attacking factors to which keratin fibres may be subjected, such as inclement weather, light, washing and perspiration. ##STR00001##

The invention provides compounds effective as sphingosine-1-phosphate receptor modulators for treatment of cardiopulmonary diseases, such as hypertension (including malignant hypertension), angina, myocardial infarction, cardiac arrhythmias, congestive heart failure, coronary heart disease, atherosclerosis, angina pectoris, dysrhythmias, cardiomyothopy (including hypertropic cardiomyothopy), heart failure, cardiac arrest, bronchitis, asthma, chronic obstructive pulmonary disease, cystic fibrosis, croup, emphysema, pleurisy, pulmonary fibrosis, pneumonia, pulmonary embolus, pulmonary hypertension, mesothelioma, ventricular conduction abnormalities, complete heart block, adult respiratory distress syndrome, sepsis syndrome, idiopathic pulmonary fibrosis, scleroderma, systemic sclerosis, retroperitoneal fibrosis, prevention of keloid formation, or cirrhosis.

The present invention relates to an unsymmetrical squaraine dye of formula (I) and process for the preparation thereof. Further, the present invention relates to an electronic device with an enhanced device efficiency containing a dye of formula (I) co-sensitized with a sqaurine dye.

##STR00001##

The present invention relates to a process for dyeing keratin fibres, in particular human keratin fibres such as the hair, in one or more steps, comprising the application to said keratin fibres of a composition comprising one or more compounds of formula (I) and/or (II), and also to the use thereof for dyeing keratin fibres, and to a device: in which formula (I) or (II) R.sub.1, R.sub.3, R.sub.4, R.sub.5, R.sub.6, and n are as defined in the description. The compounds of formula (I) according to the invention can give powerful, chromatic and sparingly selective colourings with good colour build-up, which are resistant to the various attacking factors to which keratin fibres may be subjected, such as inclement weather, light, washing and perspiration.

##STR00001##

Disclosed are compositions containing a UV-inhibitor, optionally a carrier, and optionally anions; wherein the UV-inhibitor is at least one compound of formula (I)

##STR00001##

wherein R1 is an aryl derivative, N-acyl, guanidine or aminoguanidine group, and R2 and R3 are independently an aryl group substituted with a straight or branched chain alkyl or an electron donating or withdrawing group. Also disclosed are methods for protecting a product from UV light, involving applying to said product, in an amount sufficient to protect said product from UV light, the composition. Furthermore, there is disclosed methods for providing a reversible dye to a product, involving applying to said product, in an amount sufficient to provide a visible color to said product, the composition.

The invention provides compounds effective as sphingosine-1-phosphate receptor modulators for treatment of cardiopulmonary diseases, such as hypertension (including malignant hypertension), angina, myocardial infarction, cardiac arrhythmias, congestive heart failure, coronary heart disease, atherosclerosis, angina pectoris, dysrhythmias, cardiomyothopy (including hypertropic cardiomyothopy), heart failure, cardiac arrest, bronchitis, asthma, chronic obstructive pulmonary disease, cystic fibrosis, croup, emphysema, pleurisy, pulmonary fibrosis, pneumonia, pulmonary embolus, pulmonary hypertension, mesothelioma, ventricular conduction abnormalities, complete heart block, adult respiratory distress syndrome, sepsis syndrome, idiopathic pulmonary fibrosis, scleroderma, systemic sclerosis, retroperitoneal fibrosis, prevention of keloid formation, or cirrhosis.

The present invention relates to dissymmetric azomethine direct dyes of formula (I) and the leuco forms thereof of formula (II), and also to the use thereof for dyeing keratin fibres, in particular human keratin fibres such as the hair: ##STR00001##
in which formula (I) or (II) R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, n and n are as defined in the description. The compounds of formula (I) or (II) according to the invention can give powerful, chromatic and sparingly selective colourings with good colour build-up, which are resistant to the various attacking factors to which keratin fibres may be subjected, such as inclement weather, light, washing and perspiration.

A dye composition dissolvable within a liquid crystal host device (including: polymer dispersed liquid crystal, polymer network liquid crystal, polymer stabilized liquid crystal, liquid crystal displays and similar devices), comprising eutectic mixtures of dichroic metallomesogen molecules. The aforesaid metallomesogen molecules comprise chromophore groups synthesized by physical and chemical mixing methods.